Radiation before surgery for high-risk UTUC
Part of Kidney & urinary clinical trials.
This trial tests whether giving radiation therapy before surgery can help people with high-risk upper tract urothelial cancer (UTUC). The goal is to improve treatment outcomes for patients who are planning to have their cancer removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with high-risk upper tract urothelial cancer (UTUC) that has not spread to other parts of the body.
- Your cancer was confirmed by a biopsy or tissue sample, and it may include some special cell types (like squamous or glandular, but no more than half of the tumor).
- You are willing to have surgery to remove the cancer and can follow your doctor's treatment plan.
- You have not had prior radiation to your pelvis or abdomen, and you have not had chemotherapy for any cancer.
- You are not pregnant or breastfeeding, and if you could become pregnant, you will use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests two drugs (toripalimab and 9MW2821) given before surgery for patients with upper tract urothelial cancer that hasn't spread. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Urothelial Carcinoma of the Renal Pelvis and Ureter trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.